Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 2, 2004, Pages 223-230

  Yue, Hong ^a   Uzui, Hiroyasu ^a   Shimizu, Hiromasa ^a   Nakano, Akira ^a   Mitsuke, Yasuhiko ^a   Ueda, Takanori ^a   Lee, Jong Dae ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Calcium channel blocker; Fibroblasts; Matrix metalloproteinase; Nitric oxide; Protein tyrosine kinase

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GELATINASE A; GENISTEIN; HERBIMYCIN A; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PROTEIN TYROSINE KINASE INHIBITOR; REAGENT; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COLLAGEN DEGRADATION; DRUG MECHANISM; FIBROBLAST; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ZYMOGRAPHY;

AMLODIPINE; ANIMALS; ANIMALS, NEWBORN; BENZOQUINONES; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; GENISTEIN; LACTAMS, MACROCYCLIC; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE; NITROPRUSSIDE; PROTEIN KINASE INHIBITORS; QUINONES; RATS; RATS, WISTAR; VERAPAMIL;

EID: 3242766852     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200408000-00012     Document Type: Article

References (41)

1. Mann DL, Spinal FG. Activation of matrix metalloproteinases in the failing human heart. Breaking the Tie That Binds. Circulation. 1998;98: 1699-1702.
2. Nagas H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491-21494.
3. Aimes RT, Quigley JP. Matrix Metalloproteinase-2 is an interstitial collagenase. J Biol Chem. 1995;270:5872-5876.
4. Fabunmi RP, Baker AH, Murray EJ, et al. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
5. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97: 1708-1715.
6. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001;103:2303-2309.
7. Packer M, Kessler PD, Lee WH. Calcium-channel blockade in the management of severe chronic congestive heart failure. A bridge too far. Circulation. 1987;75(Suppl V):V56-V64.
8. Sandmann S, Claas R, Cleutjens JP, et al. Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats. J Cardiovasc Pharmacol. 2001;37: 64-77.
9. Whittaker P, Zhang HP, Kloner RA. Biphasic survival response to amlodipine after myocardial infarction in rats: Association with cardiac vascular remodeling. Cardiovasc Pathol. 2000;9:85-93.
10. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil upregulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292:606-609.
11. Eghbali M, Czaja MJ, Zeydel M, et al. Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol. 1988;20:267-276.
12. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995; 27:1281-1292.
13. Goshima K. Ouabain-induced arrhythmias of single isolated myocardial cells and cell clusters in vitro and their improvement by quinidine. J Mol Cell Cardiol. 1977;9:7-23.
14. Sadoshima J, Jahn L, Takahashi T, et al. Molecular characterization of stretch-induced adaptation of cultured cardiac cells. J Biol Chem. 1992; 267:10551-10560.
15. Tyagi SC, Meyer L, Schmaltz RA, et al. Proteinases and restenosis in the human coronary artery: extracellular matrix production exceeds the expression of proteolytic activity. Atherosclerosis. 1995;116:43-57.
16. Yue H, Lee J-D, Shimizu H, et al. Effects of magnesium on the production of extracellular matrix metalloproteinases in cultured rat vascular smooth muscle cells. Atherosclerosis. 2003;166:271-277.
17. Pickering JG, Ford CM, Tang B, et al. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Evidence for repressed collagen production and activated degradative capacity. Arterioscler Thromb Vasc Biol. 1997; 17:475-482.
18. Frandsen A, Schousboe A. Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5- methylisoxazol-4-yl)propionate and kainate in cultured cerebral cortical neurons. Proc Natl Acad Sci U S A. 1992;89:2590-2594.
19. Green L, Wagner D, Glogowski J, et al. Analysis of nitrate, nitrite, and (15N)nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
20. Djuric D, Mitrovic V, Jakovljevic V. The effects of calcium channel antagonists on coronary nitrite outflow in isolated rat heart. Arzneimittelforschung. 2002;52:365-370.
21. Janicki JS, Brower GL. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail. 2002;8:S319-S325.
22. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826-831.
23. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation. 2001;103:2181-2187.
24. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem. 1996;271:14657-14660.
25. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res. 2000;86:1259-1265.
26. Verhaar MC, Honing ML, van Dam T, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res. 1999;42:752-760.
27. Herbette LG, Vant Erve YM, Rhodes DG. Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors. J Mol Cell Cardiol. 1989;21:187-201.
28. Berkels R, Egink G, Marsen TA, et al. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension. 2001;37:240-245.
29. Tsien RY. Fluorescent probes of cell signaling. Annu Rev Neurosci. 1989; 12:227-253.
30. Brilla CG, Scheer C, Rupp H. Angiotensin II and intracellular calcium of adult cardiac fibroblasts. J Mol Cell Cardiol. 1998;30:1237-1246.
31. Colston JT, Chandrasekar B, Freeman GL. A novel peroxide-induced calcium transient regulates interleukin-6 expression in cardiac-derived fibroblasts. J Biol Chem. 2002;277:23477-23483.
32. Shivakumar K, Kumaran C. L-type calcium channel blockers and EGTA enhance superoxide production in cardiac fibroblasts. J Mol Cell Cardiol. 2001;33:373-377.
33. Bellosta S, Canavesi M, Favari E, et al. Lacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. J Pharmacol Exp Ther. 2001;296:736-743.
34. Alexander JJ, Miguel R, Piotrowski JJ. The effect of nifedipine on lipid and monocyte infiltration of the subendothelial space. J Vasc Surg. 1993; 17:841-847.
35. Grieve DJ, MacCarthy PA, Gall NP, et al. Divergent biological actions of coronary endothelial nitric oxide during progression of cardiac hypertrophy. Hypertension. 2001;38:267-273.
36. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
37. Hirai Y, Migita K, Honda S, et al. Effects of nitric oxide on matrix metalloproteinase-2 production by rheumatoid synovial cells. Life Sci. 2001; 68:913-920.
38. Yoshida M, Sagawa N, Itoh H, et al. Nitric oxide increases matrix metalloproteinase-1 production in human uterine cervical fibroblast cells. Mol Hum Reprod. 2001;7:979-985.
39. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signalling. Cell. 1995;80:225-236.
40. Li L, Eisen AZ, Sturman E, et al. Protein tyrosine phosphorylation in signalling pathways leading to the activation of gelatinase A: activation of gelatinase A by treatment with the protein tyrosine phosphatase inhibitor sodium orthovanadate. Biochim Biophy Acta. 1998;1405:110-120.
41. Uzui H, Lee J-D, Shimizu H, et al. The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis. 2000;149:51-59.